HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

NEUTROGENA U.S. "UPTURN" HELPS DRIVE SECOND QUARTER SALES

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

NEUTROGENA U.S. "UPTURN" HELPS DRIVE SECOND QUARTER SALES up 9.7% to $73 mil., the company said in a May 25 financial report for the three months ended April 30. The second quarter results "reflect a strong upturn in our domestic business, which started well into our second quarter and is continuing into May," Neutrogena Chairman and CEO Lloyd Cotsen explained. In the first quarter, the firm's U.S. sales dropped 17.4% to $46.6 mil. due to declines in its bath and shower care lines and lost shipping and selling days because of the extreme weather in the East and Midwest.

Table

View full table

Tags:
Latest Headlines

People On The Move: Appointments At Haleon, Bayer, Abdi Ibrahim

AI News: Lauder Expands Microsoft Partnership; Prose Beauty; Supply Chain Software; More

Bausch + Lomb’s Prescription For Consumer Health Sales Growth Includes ‘Benefit’ From Rx Drugs

Haleon Capitalizes On Global Rebound Of Dietary Supplement Sales

See All
UsernamePublicRestriction

Register

RS000500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By